Search Results

You are looking at 81 - 90 of 126 items for :

  • "Bladder cancer" x
Clear All
Full access

Kelsey C. Stoltzfus, Biyi Shen, Leila Tchelebi, Daniel M. Trifiletti, Niraj J. Gusani, Vonn Walter, Ming Wang and Nicholas G. Zaorsky

pleural mesothelioma, no independent effects on overall survival were observed when assessing facility volume. 8 In addition, a study of patients with muscle-invasive bladder cancer found no difference in survival between patients treated at a high

Full access

Muhammed Aasim Yusuf, Vinay Kumar Kapoor, Refaat Refaat Kamel, Ather Kazmi, Najam Uddin, Nehal Masood and Abdulmajeed Al-Abdulkareem

). Regarding gall bladder cancer, the highest incidence rates worldwide were reported for women in Delhi, India (21.5/100,000); South Karachi, Pakistan (13.8/100,000); and Quito, Ecuador (12.9/100,000). 6 Risk factors for gallbladder cancer include gallstones

Full access

Jarushka Naidoo

cisplatin-ineligible bladder cancer, patients may receive atezolizumab or pembrolizumab, using 2 different PD-L1 biomarkers. Atezolizumab uses the SP142 antibody with a PD-L1 IHC cutoff of 5% for immune cells only. Pembrolizumab uses a different scoring

Full access

across different racial subgroups are warranted. CLO20-055: Optimal Timing of Radical Surgery From Diagnosis in Muscle Invasive Bladder Cancer (MIBC) Saurabh Parasramka, MD; Quan Chen, DrPH; Bin Huang, DrPH., MS; Peng Wang, MD, PhD; and Zin Myint, MD

Full access

these agents into routine care.” Several checkpoint inhibitors have already been FDA-approved for various cancers, including melanoma, Hodgkin lymphoma, and lung, liver, kidney, and bladder cancers. The use of checkpoint inhibitors is continuously

Full access

Myeloid Leukemia Bladder Cancer Breast Cancer Genetic/Familial High-Risk Assessment: Breast and Ovarian Genetic/Familial High-Risk Assessment: Colorectal Hodgkin Lymphoma Lung Cancer Screening Neuroendocrine Tumors Pancreatic Adenocarcinoma

Full access

V.1.2014; Acute Myeloid Leukemia V.2.2014; Bladder Cancer V.2.2014; Chronic Myelogenous Leukemia V.3.2014; Hodgkin Lymphoma (V.2.2013); Multiple Myeloma (V.2.2014); Myeloid Growth Factors (V.2.2013); Systemic Light Chain Amyloidosis (V.2

Full access

Nikolai A. Podoltsev, Mengxin Zhu, Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Amy J. Davidoff, Scott F. Huntington, Smith Giri, Steven D. Gore and Xiaomei Ma

: https://healthcaredelivery.cancer.gov/seermedicare/considerations/date.html . Accessed September 14, 2018. 18. Hollenbeck BK , Ye Z , Dunn RL , . Provider treatment intensity and outcomes for patients with early-stage bladder cancer . J Natl

Full access

Harish N. Vasudevan and Sue S. Yom

RT has demonstrated improved outcomes in lung cancer, 1 gastrointestinal malignancies, 2 – 4 glioblastoma, 5 bladder cancer, 6 and HNC. 7 , 8 Broadly, numerous mechanisms underlie the interactions observed between these 2 treatment modalities

Full access

Lainie Martin and Russell J. Schilder

Kraemer K . Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and cisplatin . J Urol 2005 ; 174 : 328 – 331 . 12. Sanborn RE Sandler AB